HOME   |    PDF   |   


Molecular docking analysis of imiquimod with the TGF-β targets for oral carcinoma



Jayanthi Pazhani, Vishnu Priya Veeraraghavan & Selvaraj Jayaraman*



Centre of Molecular Medicine and Diagnostics (COMManD), Department of Biochemistry, Saveetha Dental College & Hospitals, Saveetha Institute of Medical & Technical Sciences, Saveetha University, Chennai-600077, India; *Corresponding author



Jayanthi Pazhani - drjayanthip@gmail.com

Vishnu Priya Veeraraghavan -vishnupriya@saveetha.com

Selvaraj Jayaraman - selvarajj.sdc@saveetha.com



Article Type

Research Article



Received April 1, 2023; Revised April 30, 2023; Accepted April 30, 2023, Published April 30, 2023



TGF-β signalling pathway is the main signalling pathways that regulate various biological functions such as cell proliferation, apoptosis, metabolic dysregulation, and metastasis in many cancer cells. Previous studies have elaborated the role of TGF-β signalling targets have a significant regulatory function in various cancers. Moreover targeting the epithelial to mesenchymal transition markers in oral squamous cell carcinoma not yet elucidated. Therefore, it is of interest to document the molecular docking analysis of TGF-β signalling pathway targets such as Smad2, GATA2 and MAFG with imiquimod. These results suggest that targeting the TGF-β signaling pathway downstream targets with imiquimod might leads to an improved outcome as potential therapeutic options in oral carcinoma.



Oral cancer, TGF-β signaling, Imiquimod, molecular docking



Pazhani et al. Bioinformation 19(4): 467-470 (2023)


Edited by

P Kangueane






Biomedical Informatics



This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.